GRANDPHARMA subsidiary spends 316 million RMB to acquire an amino acid product company

AASTOCKS
2025.12.31 08:50

GRANDPHARMA (00512.HK) announced that its subsidiary Hubei GRANDPHARMA has entered into a share purchase agreement to acquire all equity of Hebei GRANDPHARMA Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd., with a total consideration of RMB 316 million; the two companies are engaged in the production and sales of amino acid and thiol products, respectively. One of the sellers is China GRANDPHARMA, a shareholder of GRANDPHARMA.

The company stated that the target companies possess a complete industrial chain from amino acid raw materials to end health products, with significant cost advantages, leveraging the existing mature customer base to continuously explore market pipelines in human nutrition, animal nutrition, and personal care and daily chemical fields, implementing a "diversification development strategy."

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer